De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Gland Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Gland Pharma heeft een totaal eigen vermogen van ₹87.2B en een totale schuld van ₹3.7B, wat de schuld-eigenvermogensverhouding op 4.3% brengt. De totale activa en totale passiva bedragen respectievelijk ₹106.6B en ₹19.4B. De EBIT Gland Pharma is ₹9.3B waardoor de rentedekking 34.7 is. Het heeft contanten en kortetermijnbeleggingen van ₹18.4B.

Belangrijke informatie

4.3%

Verhouding schuld/eigen vermogen

₹3.72b

Schuld

Rente dekkingsratio	34.7x
Contant	₹18.39b
Aandelen	₹87.24b
Totaal verplichtingen	₹19.37b
Totaal activa	₹106.61b

Recente financiële gezondheidsupdates

Recent updates

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Oct 01

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Sep 05

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 09

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Jun 22

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

May 25

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Mar 19

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Feb 16

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

May 20

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 07

Analysts Just Slashed Their Gland Pharma Limited (NSE:GLAND) EPS Numbers

Jul 22

Does This Valuation Of Gland Pharma Limited (NSE:GLAND) Imply Investors Are Overpaying?

Jul 14

Is Now The Time To Put Gland Pharma (NSE:GLAND) On Your Watchlist?

Feb 08

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹56.5B ) GLAND } overtreffen de korte termijn passiva ( ₹14.0B ).

Langlopende schulden: De kortetermijnactiva GLAND ( ₹56.5B ) overtreffen de langetermijnschulden ( ₹5.4B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: GLAND heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van GLAND is de afgelopen 5 jaar gestegen van 0.2% naar 4.3%.

Schuldendekking: De schuld van GLAND wordt goed gedekt door de operationele kasstroom ( 267.8% ).

Rentedekking: De rentebetalingen op de schuld van GLAND worden goed gedekt door EBIT ( 34.7 x dekking).

Gland Pharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Recent updates

Gland Pharma (NSE:GLAND) Has A Pretty Healthy Balance Sheet

Insufficient new directors

Gland Pharma Limited Announces Executive Changes

Investors Still Waiting For A Pull Back In Gland Pharma Limited (NSE:GLAND)

Gland Pharma Limited Announces Board Changes

Consensus EPS estimates fall by 16%

Gland Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Gland Pharma Limited to Report Q4, 2025 Results on May 20, 2025

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Gland Pharma Receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma Limited to Report Q1, 2025 Results on Aug 06, 2024

Insider recently sold ₹24m worth of stock

Does Gland Pharma (NSE:GLAND) Have A Healthy Balance Sheet?

Fosun Pharma Industrial Reportedly to Pare 5% Stake in Gland Pharma for $172 Million

Head of Quality recently sold ₹8.3m worth of stock

Insider recently sold ₹9.2m worth of stock

Gland Pharma Limited Announces Management Changes

Insufficient new directors

Gland Pharma Limited Announces Resignation of C.S. Venkatesan as Sr. Vice President (R&D) and SMP, Effective June 30, 2024 and July 1, 2024 Respectively

Consensus EPS estimates fall by 14%, revenue upgraded

Earnings Miss: Gland Pharma Limited Missed EPS By 15% And Analysts Are Revising Their Forecasts

Gland Pharma Limited, Annual General Meeting, Aug 30, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q4, 2024 Results on May 22, 2024

Gland Pharma Limited Approves Appointment of Mr. Satnam Singh Loomba as Chief Operating Officer, Effective May 1 ,2024

Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals

Chief Technical Officer recently sold ₹14m worth of stock

Is Gland Pharma (NSE:GLAND) A Risky Investment?

Chief Operating Officer recently sold ₹2.8m worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Gland Pharma Limited's (NSE:GLAND) Share Price Matching Investor Opinion

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Chief Technical Officer recently sold ₹27m worth of stock

Chief Technical Officer recently sold ₹27m worth of stock

New minor risk - Insider selling

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2024 Results on Nov 06, 2023

Chief Technical Officer recently sold ₹10m worth of stock

Gland Pharma Limited Appoints Ankit Gupta as Vice-President (Strategy & Investments)

Investor sentiment improves as stock rises 23%

Gland Pharma Limited Appoints Prakash Vithal Baliga as Chief Operating Officer

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q1, 2024 Results on Aug 07, 2023

Investor sentiment deteriorates as stock falls 31%

Price target decreased by 12% to ₹1,520

Analysts' Revenue Estimates For Gland Pharma Limited (NSE:GLAND) Are Surging Higher

Gland Pharma Limited, Annual General Meeting, Aug 31, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹1.3m worth of stock

Insider recently sold ₹683k worth of stock

Investor sentiment improves as stock rises 16%

Insider recently sold ₹756k worth of stock

Is Gland Pharma Limited (NSE:GLAND) Expensive For A Reason? A Look At Its Intrinsic Value

Price target decreased by 13% to ₹2,119

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Gland Pharma Limited to Report Q3, 2023 Results on Jan 23, 2023

Insider recently sold ₹798k worth of stock

Insider recently sold ₹869k worth of stock

Fosun Reportedly Planning Sale of Gland Pharma

China's Fosun Reportedly Said to Mull Sale of India's $3.6 Billion Gland Pharma

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gland Pharma Limited to Report Q2, 2023 Results on Oct 26, 2022

Insider recently sold ₹4.1m worth of stock

Insider recently sold ₹2.3m worth of stock

Gland Pharma Limited Announces Xiaohui Guan and Yifang Wu Not Offer for Reappointment as Directors

Insider recently sold ₹1.6m worth of stock

Insider recently sold ₹1.4m worth of stock

Insider recently sold ₹2.3m worth of stock

Consensus revenue estimates fall by 16%

Price target decreased to ₹3,033